Characteristic (%) | ATG (N = 363) | CD34 (N = 162) | p |
---|---|---|---|
Patient age, median (range) | 46 (19–77) | 58 (20–73) | < 0.001 |
Year of transplant | 2012 (2005–2015) | 2011 (2005–2015) | |
Patient gender | |||
Male | 200 (55%) | 90 (56%) | 0.92 |
Female | 163 (45%) | 72 (44%) | |
Female donor to male patient | 65 (18%) | 37 (23%) | 0.19 |
Karnofsky performance scale | |||
≥ 90% | 258 (76%) | 100 (63%) | 0.003 |
< 90% | 83 (24%) | 59 (37%) | |
unknown | 22 | 3 | |
CMV serologic status | |||
Seronegative donor-recipient pair | 114 (32%) | 49 (33%) | 0.4 |
Time from diagnosis to transplant, months (range) | 4.9 (1.9–14.3) | 4.3 (1.7–11.4) | 0.001 |
Cytogenetic | |||
Intermediate | 259 (71%) | 112 (69%) | 0.61 |
Poor | 104 (29%) | 50 (31%) | |
Donor | |||
Matched related donor | 118 (33%) | 73 (45%) | 0.006 |
Unrelated donor | 245 (67%) | 89 (55%) | |
Conditioning regimen | |||
Busulfan + fludarabine | 173 (48%) | 0 | < 0.0001 |
Busulfan + cycloclophosphamide | 129 (36%) | 0 | |
TBI + cyclophosphamide | 61 (17%) | 0 | |
Busulafan + fludarabine + melphalan | 0 | 107 (66%) | |
TBI + cycloclophosphamide + thiotepa | 0 | 45 (28%) | |
TBI + fludarabine + thiotepa | 0 | 10 (6%) | |
GVHD prophylaxis | |||
CsA | 62 (17%) | – | – |
CsA + MMF | 210 (58%) | – | |
CsA + MTX | 65* (18%) | – | |
Tacrolimus + sirolimus | 10 (3%) | – | |
PT Cy | 5 (1%) | – | |
Others | 11 (3%) | – | |
Antithymocyte globuline | |||
Thymoglobulin (median dose, mg/kg; range) | 233 (5; 5–7.5) | 143 (5; 2–5) | |
Grafalon, (median dose, mg/kg; range) | 130 (35; 8–60) | 0 | |
Equine ATG, (median dose, mg/kg; range) | 0 | 12 (30; 15–30) | – |
Cells doses | |||
CD34+ cells, × 106/kg (range) | 6.13 (1.64–21.2) | 8.18 (1.1–31.2) | < 0.0001 |
CD 3+ cells, × 106/kg (range) | 213 (1.13–643) | 0.002 (0–0.063) | < 0.0001 |